Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

Ruxolitinib can cause cytopenia, the most prominent adverse event (AE). There are rates of anemia and thrombocytopenia in ...

A review by authors from China examines evidence involving different treatment approaches. When ruxolitinib (Jakafi, Incyte) is given to patients with myelofibrosis in the period before and after ...

Using NGS in prognostic assessments enhances myelofibrosis prognosis and survival estimates, representing a step toward personalized medicine in myelofibrosis.

Advancing Myelofibrosis Treatment: What Lies Ahead Video content above is prompted by the following: From a patient perspective, what are some financial toxicity considerations that should be ...

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape. EP: 1 . Myelofibrosis Overview: US ...

A team of 9 hematology experts offer their recommendations regarding several practical aspects of myelofibrosis care. In a letter to the editor of Leukemia, Koschmieder and colleagues described the ...

INCA-033989 is under clinical development by Incyte and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs for Myelofibrosis have an 86% phase transition success rate (PTSR ...

Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...